It takes more than a pandemic to stop medical device companies merging.
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
2019 was an average year for medtech M&A. 2020, not so much.
The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine.